Downward Trends in Proteomics Deal Making
This article was originally published in Start Up
Executive SummaryFor more than a year, VCs have backed away from the proteomics tools group--drug companies hadn't signed the expected number and value of deals with them, and it was deal revenues that were, according to most business plans, going to support these start-ups. That pharma and biotech companies have a bigger appetite for products than for platform technology has become a truism. Licensors increasingly are finding that they must offer partners more than a discovery technology platform-either by validating targets and building value before out-licensing, or at least having the biological capability in-house to be a true collaborator.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.